Fedha

Hisa unazofuatilia
GSK:LON
GSK plc
GBX 1,770.83
+1.19%
(+20.83) Siku 1
12 Okt, 18:17:16 GMT +1  ·   GBX
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya GSK...
Fungua
GBX 1,755.00
Juu
GBX 1,771.00
Chini
GBX 1,751.00
Mtaji wa soko
94.47B
Wastani wa kiasi cha mauzo
5.90M
Kiasi cha mauzo ya hisa
3.15M
Gawio
3.84%
Mgawo wa faida wa kila robo mwaka
GBX 17.00
Tarehe ya kutojumuisha gawio
13 Ago 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
15.01
Juu kwa wiki 52
GBX 2,282.00
Chini kwa wiki 52
GBX 1,592.00
EPS
GBX 1.18
Hisa za wawekezaji
4.32B
Idadi ya wafanyakazi
elfu 67
Fungua
GBX 1,755.00
Juu
GBX 1,771.00
Chini
GBX 1,751.00
Mtaji wa soko
94.47B
Wastani wa kiasi cha mauzo
5.90M
Kiasi cha mauzo ya hisa
3.15M
Gawio
3.84%
Mgawo wa faida wa kila robo mwaka
GBX 17.00
Tarehe ya kutojumuisha gawio
13 Ago 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
15.01
Juu kwa wiki 52
GBX 2,282.00
Chini kwa wiki 52
GBX 1,592.00
EPS
GBX 1.18
Hisa za wawekezaji
4.32B
Idadi ya wafanyakazi
elfu 67
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Kuhusu GSK plc
Afisa Mkuu Mtendaji (CEO)Emma Walmsley | Emma Walmsley
Wafanyakazielfu 66.8
Lilianzishwa27 Des 2000
Makao makuu-
Sekta-
Tovutigsk.com
Ripoti za awaliThamani zote katika GBP
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika GBP
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
8.55B
8.62B
7.63B
8.41B
Gharama ya bidhaa zilizouzwa
2.24B
2.62B
1.87B
2.07B
Gharama ya mapato
2.24B
2.62B
1.87B
2.07B
Gharama za utafiti na maendeleo
1.58B
2.14B
1.52B
1.75B
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
2.16B
2.67B
2.08B
2.19B
Gharama ya uendeshaji
3.23B
4.37B
2.99B
3.74B
Jumla ya gharama za uendeshaji
5.46B
6.99B
4.86B
5.81B
Mapato ya uendeshaji
3.08B
1.63B
2.77B
2.60B
Mapato mengine yasiyo ya uendeshaji
-
-21.00M
-
-
EBT ikijumuisha vipengee visivyo vya kawaida
2.46B
950.00M
2.14B
354.00M
EBT bila kujumuisha vipengee visivyo vya kawaida
2.94B
1.48B
2.62B
2.48B
Gharama ya kodi ya mapato
312.00M
223.00M
305.00M
-199.00M
Kiwango cha kodi kinachotumika
12.70%
23.47%
14.23%
-56.21%
Gharama nyingine za uendeshaji
-511.00M
-434.00M
-615.00M
-204.00M
Mapato halisi
2.01B
636.00M
1.74B
435.00M
Kiwango cha faida halisi
23.55%
7.38%
22.77%
5.17%
Mapato kwa kila hisa
0.55
-
-
-
Mapato ya riba na uwekezaji
26.00M
17.00M
22.00M
58.00M
Gharama ya riba
-167.00M
-145.00M
-167.00M
-182.00M
Jumla ya gharama halisi za riba
-141.00M
-128.00M
-145.00M
-124.00M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
3.82B
2.69B
3.23B
2.82B
Faida au hasara kutokana na uuzaji wa vipengee
-
-40.00M
-
-
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
Programu za Google